Drug
Pamrevlumab
Status:
Phase 3
Condition:
Idiopathic Pulmonary Fibrosis
Intervention Type:
Intravenous (IV) Injection
Funder Type:
Industry
Drug Details
Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.
Study Purpose
This is a Phase 3 trial to evaluate the efficacy and safety of 30 mg/kg intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in subjects with Idiopathic Pulmonary Fibrosis.
Find a Clinical Trial